Andreas Brink is a Senior Director of Biotransformation and ADME at Eli Lilly and Company, a position held since 2025. They bring extensive experience in drug metabolism, ADME profiling, pharmacokinetics, and toxicology, having previously served as a Senior Principal Scientist at Roche from 2020 to 2025. Andreas earned a Dr. rer. nat. from Julius-Maximilians-Universität Würzburg and completed a Diplom at Universität Bayreuth. Their commitment to scientific integrity and quality is evident in their leadership of laboratory teams throughout their career.
This person is not in any teams
This person is not in any offices